REGISTER
Sun Yat-sen University Cancer Center: 8 Studies at WCLC 2026
Eight studies from Sun Yat-sen University Cancer Center, led by Prof. Li Zhang, will be presented at WCLC 2026 in Seoul (1 plenary, 3 oral, 4 mini-oral). Topics include Tam-Peli (B7-H3 ADC) vs topotecan in relapsed SCLC, Sac-TMT (TROP2 ADC) in NSCLC with non-classical EGFR alterations, RC148 (PD-1/VEGF bispecific) plus chemotherapy, and several early-phase trials of novel bispecifics and trispecifics.

The 27th World Conference on Lung Cancer (WCLC) will be held in Seoul, Korea, from September 12 to 15, 2026. As one of the major international meetings in thoracic oncology, the congress will gather leading researchers from around the world.

According to the report, eight studies led by Prof. Li Zhang from Sun Yat-sen University Cancer Center have been accepted to the meeting, including 1 plenary, 3 oral, and 4 mini-oral presentations.

Plenary Presentation

Abstract PL02.03

Title: Tam-Peli, an Anti-B7-H3 Antibody-Drug Conjugate, Versus Topotecan in Relapsed SCLC: A Randomized, Open-Label, Phase 3 Study

Presenter: Prof. Li Zhang

Research data are pending release. Further details are awaited.

Oral Presentations

Abstract OA10.03

Title: Sac-TMT in Patients With Previously Treated Advanced NSCLC With Actionable Genomic Alterations Other Than Classic EGFR Mutations

Presenter: Prof. Wenfeng Fang

Overview: Sac-TMT is a TROP2-targeted antibody-drug conjugate (ADC) that uses a bifunctional linker to conjugate a belotecan derivative to the antibody. This presentation reports preliminary efficacy and safety data from a Chinese phase II, open-label, multi-cohort study (NCT05631262) of Sac-TMT in patients with advanced NSCLC harboring actionable genomic alterations (AGA) other than classic EGFR mutations.

Patients received Sac-TMT at 5 mg/kg every 2 weeks until disease progression or unacceptable toxicity. Tumor response was assessed per RECIST v1.1 every 8 weeks for the first 48 weeks and every 12 weeks thereafter.

As of December 11, 2025, 90 patients had been enrolled (median age 59 years; 43.3% male), including 23 with EGFR mutations, 20 with EGFR exon 20 insertions, 20 with ALK fusions, 16 with KRAS mutations, and 11 with ROS1 fusions or other alterations. At a median follow-up of 21.2 months, single-agent Sac-TMT showed durable antitumor activity across all AGA subgroups, with an objective response rate (ORR) of 34.4% (31/90) and a median duration of response (DOR) of 12.7 months. Grade ≥3 treatment-related adverse events (TRAEs) occurred in 56.7% of patients, and treatment-related serious adverse events (TRSAEs) in 18.9%. The most common grade ≥3 TRAEs were decreased neutrophil count (42.2%), decreased white blood cell count (24.4%), anemia (17.8%), and stomatitis (7.8%). No TRAE-related treatment discontinuations or deaths were reported.

Sac-TMT monotherapy showed antitumor activity and a manageable safety profile in previously treated patients with advanced NSCLC harboring AGA beyond classic EGFR mutations, supporting further investigation.

Abstract OA14.04

Title: RC148 (ABBV-1480, a PD-1/VEGF Bispecific Antibody) Plus Chemotherapy in First-Line Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Presenter: Prof. L. Zhang

Overview: RC148 (ABBV-1480) is a novel bispecific antibody targeting PD-1 and VEGF. This presentation reports a study of RC148 plus platinum-based chemotherapy as first-line treatment for NSCLC.

Treatment-naive patients with unresectable NSCLC without actionable genomic alterations (AGA) were enrolled. Patients with squamous NSCLC (sq-NSCLC) received RC148 plus carboplatin/paclitaxel, while those with non-squamous NSCLC (nsq-NSCLC) received RC148 plus carboplatin/pemetrexed, at RC148 doses of 10 or 20 mg/kg. The primary endpoint was ORR; secondary endpoints included disease control rate (DCR), DOR, progression-free survival (PFS), overall survival (OS), and safety.

As of the data cutoff, 61 sq-NSCLC and 60 nsq-NSCLC patients had been enrolled. In cohort 1, RC148 10 mg/kg produced an ORR of 90.0% (95% CI 73.5-97.9), with an ORR of 93.3% in PD-L1-negative (TPS<1%) patients. PFS was 10.8 months. In cohort 2, RC148 10 mg/kg produced an ORR of 75.9%, with an ORR of 71.4% in PD-L1-negative patients. No grade ≥3 bleeding events occurred in the 10 mg/kg dose group. The most common TRAEs in both cohorts were decreased white blood cell count, decreased neutrophil count, anemia, and decreased platelet count. In cohort 1, grade ≥3 TRAEs occurred in 66.7% (10 mg/kg) and 71.0% (20 mg/kg) of patients; in cohort 2, in 70.0% and 76.7%, respectively.

RC148 plus chemotherapy demonstrated antitumor activity and a manageable safety profile as first-line treatment for NSCLC. The 10 mg/kg dose showed high activity across histologies and PD-L1 expression levels, and is recommended for the subsequent phase 3 study.

Abstract OA09.01

Title: Effect of Thymosin α-1 on Treatment Completion and Pneumonitis in Chemoradiation Plus Immunotherapy for LA-NSCLC: A Randomized Phase II Trial

Presenter: Prof. Bo Qiu

Overview: Consolidation immunotherapy after concurrent chemoradiotherapy (CCRT) has been shown to improve survival in patients with locally advanced NSCLC (LA-NSCLC), but early treatment interruption due to pneumonitis and disease progression remains a clinical challenge. Thymosin α-1 (Tα1) is an immunomodulator that may support immune reconstitution. This phase II trial evaluated the effect of Tα1 on treatment completion and pneumonitis risk in patients receiving CCRT plus immunotherapy.

In this prospective, randomized, phase II study, patients with unresectable LA-NSCLC received induction chemoimmunotherapy followed by CCRT and tislelizumab consolidation. Patients were randomized 1:1 to a Tα1 group or a control group, both receiving induction chemoimmunotherapy, CCRT, and tislelizumab consolidation; the Tα1 group also received Tα1 during treatment. The primary endpoint was the 12-month completion rate of consolidation immunotherapy. Secondary endpoints included the incidence of grade ≥2 pneumonitis and PFS. A parallel real-world study (RWS) cohort of patients receiving standard treatment (consolidation immunotherapy after CCRT) was included for comparison.

From July 2023 to April 2025, 114 patients were enrolled (57 per group). At a median follow-up of 19.6 months, the 12-month completion rate of consolidation immunotherapy was 66.0% in the Tα1 group versus 43.6% in the control group (P=0.034), and the incidence of grade ≥2 pneumonitis was 21.1% versus 38.6% (P=0.039). The 18-month PFS was 67.3% (95% CI 54.4-83.3) in the Tα1 group versus 51.0% (95% CI 39.0-66.8) in the control group (HR=0.552, log-rank P=0.048). In the RWS cohort (n=61), the 12-month completion rate was 41.0%, the incidence of grade ≥2 pneumonitis was 45.9%, and the 18-month PFS was 40.4% (95% CI 29.0-56.2).

Adding Tα1 to CCRT improved the 12-month consolidation immunotherapy completion rate, reduced the incidence of grade ≥2 pneumonitis, and showed a PFS benefit in LA-NSCLC patients.

Mini-Oral Presentations

Abstract MO06.08

Title: Long-Term Outcomes Following Neoadjuvant SBRT Combined With Immunochemotherapy in Stage II-III NSCLC

Presenter: Prof. H. Yang

Overview: Neoadjuvant stereotactic body radiation therapy (SBRT) plus immunochemotherapy has been shown to improve short-term outcomes in patients with resectable NSCLC. This presentation reports long-term results from the SACTION01 trial.

SACTION01 is an open-label, single-arm, phase II study in patients with resectable stage IIA to IIIB NSCLC. Patients received SBRT to the primary tumor (24 Gy in 3 fractions), followed by 2 cycles of tislelizumab (200 mg) plus platinum-based chemotherapy, with surgery 4-6 weeks after completion of neoadjuvant therapy. The primary endpoint was major pathologic response (MPR); secondary endpoints included event-free survival (EFS) and OS. Multiplex immunofluorescence was used to explore changes in the tumor microenvironment.

At a median follow-up of 42 months, the 48-month EFS and OS were 64.6% (95% CI 48.6-76.3) and 81.7% (95% CI 64.4-91.0), respectively. Of 46 patients, 24 (52.2%) achieved pathologic complete response (pCR), but pCR was not significantly associated with EFS (HR=0.46, 95% CI 0.17-1.25; P=0.13) or OS (HR=2.14, 95% CI 0.48-9.44; P=0.35). A total of 35 patients (76.1%) achieved MPR, which was also not significantly associated with EFS (HR=0.59, 95% CI 0.18-1.95; P=0.32) or OS (HR=0.61, 95% CI 0.10-3.95; P=0.55). No treatment-related deaths, unexpected long-term toxicities, or other safety issues occurred. Compared with immunochemotherapy alone, SBRT plus immunochemotherapy increased the abundance of tertiary lymphoid structures, suggesting that SBRT may remodel the tumor microenvironment.

These survival data support incorporating SBRT into induction immunochemotherapy for patients with resectable stage IIA-IIIB NSCLC, with potential long-term benefit. The ongoing phase 3 SACTION2401 trial (NCT06598527) is further evaluating this regimen, comparing induction immunochemotherapy with or without SBRT.

Abstract MO07.06

Title: Phase II Study of Opamtistomig (LBL-024), a PD-L1/4-1BB Bispecific Antibody Plus Chemotherapy in First-Line Advanced NSCLC

Presenter: Prof. Yan Huang

Overview: Opamtistomig is a PD-L1/4-1BB bispecific antibody that simultaneously inhibits PD-L1-mediated immune suppression and enhances T cell co-stimulation. This phase II study evaluated the efficacy and safety of opamtistomig plus chemotherapy as first-line treatment for locally advanced or metastatic NSCLC, with a focus on treatment-naive nsq-NSCLC (cohort 2A) and sq-NSCLC (cohort 2B) patients.

As of March 6, 2026, 63 patients had been enrolled (31 nsq-NSCLC, 32 sq-NSCLC), with a median follow-up of 3.6 months. Among 60 evaluable patients, the ORR was 65.0%, with 51.7% in nsq-NSCLC and 77.4% in sq-NSCLC. ORR was 78.3% in patients with PD-L1 TPS≥1% and 59.4% in those with TPS<1%; DCR was high in both groups. Grade ≥3 TRAEs occurred in 28.6% of patients. The most common TRAEs were anemia (55.6%), leukopenia (42.9%), and neutropenia (39.7%). No new safety signals were reported.

Opamtistomig plus chemotherapy showed preliminary antitumor activity in treatment-naive NSCLC, with an overall manageable safety profile, supporting further investigation.

Abstract MO07.07

Title: First-in-Human Study of HC010, a Novel PD-1/VEGF/CTLA-4 Trispecific Antibody: Preliminary Results

Presenter: Prof. Yuxiang Ma

Overview: HC010 is a humanized trispecific antibody targeting PD-1, CTLA-4, and VEGF. This phase I study evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of HC010 monotherapy in patients with advanced solid tumors.

As of December 22, 2025, 79 patients had been enrolled in the dose-escalation phase, of whom 53 had NSCLC. Most patients had received ≥2 prior lines of therapy, and 68.4% had received prior immunotherapy. The maximum tolerated dose had not been reached; one dose-limiting toxicity occurred in the 15 mg/kg Q2W group. TRAEs occurred in 93.7% of patients, with grade ≥3 TRAEs in 24.1%. The most common TRAEs were rash (38.0%), hypothyroidism (22.8%), alanine aminotransferase (ALT) elevation (20.3%), aspartate aminotransferase (AST) elevation (20.3%), and anemia (20.3%). Among 69 evaluable patients, the ORR was 14.5% and the DCR was 71%. In 12 patients with immunotherapy-resistant NSCLC, the ORR was 25% and the DCR was 75%.

HC010 monotherapy showed a manageable safety profile and preliminary antitumor activity across multiple advanced solid tumors, supporting further development as monotherapy and in combination regimens.

Abstract MO15.04

Title: First-Line YL201 Plus Serplulimab in ES-SCLC and Advanced NSCLC: Phase 1 Results of a B7-H3-Directed Combination Strategy

Presenter: Prof. Hongyun Zhao

Overview: YL201 is a B7-H3-targeted ADC. This phase I study evaluated the efficacy and safety of YL201 plus serplulimab as first-line treatment for ES-SCLC and advanced NSCLC.

Based on dose-escalation results, YL201 at 2.0 mg/kg was identified as the recommended dose. Patients received YL201 plus serplulimab every 3 weeks. As of March 13, 2026, 85 treatment-naive patients had been enrolled, including 41 with ES-SCLC, 24 with nsq-NSCLC without AGA, and 19 with sq-NSCLC.

The confirmed ORR in ES-SCLC patients was 85.4%, with a median PFS of 12.9 months; median OS had not been reached at a median follow-up of 12.1 months. The confirmed ORR was 58.3% in nsq-NSCLC and 57.9% in sq-NSCLC, with median PFS not reached and 11.7 months, respectively. Grade ≥3 TRAEs occurred in 38.8% of patients, with no new safety signals identified. No clear correlation was observed between B7-H3 expression levels or PD-L1 expression status and confirmed ORR.

0
0
Loading